Imagion Biosystems is pleased to announce a pro-rata renounceable rights issue (Offer) to fund the manufacture of the nanoparticle material, the undertaking of a first-in-human study (where sufficient capital is raised), and for general working capital purposes.
Read the Pro-Rata Renounceable Rights Issue.
Imagion Initiates Collaboration with Wayne State University to Develop Advanced Molecular Imaging Capabilities to Enable AI Cancer Diagnostics
August 13, 2025
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilizing its proprietary MagSense® imaging